

<h3>Bibliografía</h3>

    <ol>
        <li>Hunth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of pacientes with acquired hemophilia A. Haematologica 2009;94:566-75.</li>
        <li>Knoelb P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012;10:622-31.</li>
        <li>Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol 2017;92(7):695-705.</li>
        <li>Mingot-Castellano ME, Núñez R, Rodríguez-Martorell FJ. Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. Med Clin (Barc); 2017;148(7):314-22.</li>
        <li>Franchini M, Vaglio S, Marano G, Mengoli C, Gentili S, Pupella S, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology 2017;22(9):514-20.</li>
        <li>André S, Meslier Y, Dimitrov J, Repessé Y, Kaveri S, Lacroix-Desmazes S, et al. A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. Clinic Rev Allerg Immunol 2009;37:105-13.</li>
        <li>Wootla B, Desirazu N, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri S. Varied Immune Response to FVIII: Presence of Proteolytic Antibodies Directed to Factor VIII in Different Human Pathologies. Clinic Rev Allerg Immunol 2009;37:97-104.</li>
        <li>Lavigne-Lissalde G, Rothschild C, Pouplard C, Lapalud P, Gruel Y, Schved J, et al. Characteristics, Mechanisms of Action, and Epitope Mapping of Anti-factor VIII Antibodies. Clinic Rev Allerg Immunol 2009;37:67-79.</li>
        <li>Nemes L, Tengborn L, Collins PW, Baudo F, Huth-Kuehne A, Knoebl P, et al. Acquired Haemophilia and pregnancy/postpartum- a Report from an European Acquired Registry. Blood 2010;116:717.</li>
        <li>Collins PW, Chalmers E, Hart D, Jennings I, Liesner R, Rangarajan S, et all. On behalf of United Kingdom Haemophilia Centre Doctors’ Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013;162(6):758-73.</li>
        <li>Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Lászlós N et al. Management of bleeding in acquired hemophilia A: results from the European Acquired haemophilia (EACH2) Registry. Blood 2012;120:39-46.</li> 
        <li>Dunkley SM, Yang K. The use of combination FEIBA and rFVIIa bypassing therapy with TEG profiling in uncontrollable bleeding associated with acquired haemophilia A. Haemophilia 2009;15:828-30.</li>
        <li>Al-Mondhiry HAB, Ma A, Kessler CM, Fisher M, Gut RZ, Cooper DL. US experience with recombinant factor VIIa (rFVIIa) for surgery in acquired hemophilia (AH): analysis from the Hemostasis and Thrombosis Research Society (HTRS) registry. Blood 2012;120:3372.</li>
        <li>Takedani H, Shima M, Horikoshi Y, Koyama T, Fukutake K, Kuwahara M, et al. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia 2015;21:374-9.</li>
        <li>Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015;21:162-70.</li>
        <li>Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, Roca CA, Hirnyk MI, Jiménez-Yuste V, et al. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. Eur J Haematol 2016;96(5):461-74.</li>
        <li>Zanon E, Milan M, Gamba G, Ambaglio C, Saggiorato G, Spiezia L, et al. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study. Thromb Res 2015;136:1299-302.</li>
        <li>Muto A, Yoshihashi K, Takeda M, Kitazawa T, Soeda T, Igawa T, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014;124(20):3165-71.</li>
        <li>Tiede A, Scharf RE, Dobblestein C, Werwitzke S. Management of acquired haemophilia A. Häemostaseologie 2015;35(4):311-8.</li>
        <li>Tiede A, Klamroth R, Scharf RE, Holstein K, Huth-Kühne A, Gottstein S, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015;125:1091-7.</li>
        <li>Delgado J, Jiménez-Yuste V, Hernández-Navarro F, Villar A. Acquired haemophilia: review and meta analysis focused on therapy and prognostic factors. Br J Haematol 2003;121(1):21-35.</li>
        <li>Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis 2009;20:517-23.</li>
        <li>Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pelegrini F, et al. Immunosuppression for acquired haemophilia A: results from de European Acquired Haemophilia Registry (EACH2). Blood 2012;120(1):47-55.</li>
    </ol>